Clinical trial
A 10-Week, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17
NCT00754052 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A 10-Week, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17
- Lead sponsor
- Eisai Inc.
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- September 30, 2008
- Completion date
- December 31, 2008
- Enrollment
- 8 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.